Radiation oncology vendor Varian Medical Systems has garnered a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its cardiac radioablation system.
Varian said it's currently developing the system as a noninvasive therapy for select patients with refractory ventricular tachycardia. Unlike conventional catheter ablation for ventricular tachycardia, Varian's system targets and delivers ablative energy across the full thickness of the myocardium, according to the Siemens Healthineers company.
